Nevertheless, several studies demonstrate that PXR promotes tumor sensitivity to chemotherapeutic agents by regulating the gene expression of drug transporters and via its implication in several metabolic processes that influence the treatment outcome of many antineoplastic agents, including taxanes, platinum-based agents, and antihormone agents (such as paclitaxel, cisplatin, tamoxifen), as well as topoisomarase-I inhibitors such as doxorubicin and ixabepilone [13,14]. This evidence concerns the gene NR1I2 and neoplasm.